key: cord-0967042-yhgtt6ii
authors: Kawasuji, H.; Tsuji, Y.; Ogami, C.; Takegoshi, Y.; Kaneda, M.; Murai, Y.; Kimoto, K.; Ueno, A.; Miyajima, Y.; Fukui, Y.; Nagaoka, K.; Sakamaki, I.; Morinaga, Y.; Yamamoto, Y.
title: Association between high serum favipiravir concentrations and drug-induced liver injury
date: 2021-05-04
journal: nan
DOI: 10.1101/2021.05.03.21256437
sha: 906f80627fd74a8172a32333e655b075e11b3e5c
doc_id: 967042
cord_uid: yhgtt6ii

Objectives This study aimed to evaluate the incidence and pattern of favipiravir-induced liver injury and the potential association between serum concentrations in hospitalized COVID-19 patients. Patients and methods We retrospectively reviewed laboratory-confirmed patients with COVID-19 for whom serum favipiravir trough concentration (Cmin) was measured under steady-state conditions during treatment. All patients were administered 1800 mg of favipiravir twice daily on the first day and 800 mg twice daily from the second day. Results Thirty observed favipiravir concentrations were collected from nine patients. Of these, favipiravir-induced liver injury developed in three patients after 13 (11-14) days from the initiation of therapy, with two classified as cholestatic and one hepatocellular injury, with a score of four (possible), seven (probable), and three (possible) based on the CIMOS/RUCAM scoring system. Median (range) favipiravir Cmin at steady state was found to be significantly higher in patients with liver injury at 66.4 (47.8-72.4) mg/L than in those without injury at 12.8 (9.4-21.8) mg/L(P = 0.028). Conclusions Higher favipiravir serum concentrations were observed in patients who developed favipiravir-induced liver injury than in those who did not. As the variations in favipiravir concentrations between patients were large, personalized optimal dosing strategies may be needed for safe use.

Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-2 coronavirus 2 (SARS-CoV-2) has rapidly spread to more than 200 countries, with more than 1. 4 3 hundred million confirmed cases and 3.0 million deaths to date [1] . Various drugs have been 4 used to treat patients with COVID-19, and their efficacy has been evaluated to identify a 5 breakthrough therapy. 6

Favipiravir is a modified pyrazine analog that inhibits RNA-dependent RNA polymerases, 7 which ultimately prevents viral transcription and replication of RNA viruses. Favipiravir, which 8 was initially developed by Toyama Chemical Co., Ltd., as a drug to treat the influenza virus 9 infection, is expected to exhibit antiviral activity against SARS-CoV-2; however, information 10 about its efficacy, particularly its related pharmacokinetics, remains limited. 11

The recommended dosing protocol for favipiravir in COVID-19 is 1800 mg twice a day 12 on day 1 and 800 mg twice a day from day 2 to 10 days (maximum 14 days). Although 13 favipiravir is regarded as safe in various studies, the risks of teratogenicity, hyperuricemia, and 14 drug fever should be considered [2, 3] . Elevated blood uric acid levels are a frequent side effect 15 of favipiravir. However, blood uric acid levels normalize quickly after discontinuation of 16 favipiravir, and few symptoms due to hyperuricemia have been observed in most studies [4] . 17

Subsequently, abnormal liver tests and/or liver injury are also important adverse effects observed 18 frequently in some clinical trials [5, 6] , which sometimes lead to discontinuation of therapy; 19 however, case reports on favipiravir-induced liver injury are limited, and no previous study has 20

reported an association between favipiravir-induced liver injury and serum concentrations [7] . 21

The present study aimed to investigate the variations in favipiravir serum concentrations 22 during treatment between individual patients and evaluate the incidence and pattern of 23 favipiravir-induced liver injury, and the potential association between serum concentrations in 24 laboratory-confirmed hospitalized patients with COVID-19. 25 26 27 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; 1 

Clinical data, including favipiravir concentrations, were collected from laboratory-3 confirmed patients with COVID-19 who were admitted to Toyama University Hospital from 4

April 2020 to February 2021 and treated using favipiravir. Patients with at least one favipiravir 5 serum C min measured under steady-state conditions, a minimum of 48 h after favipiravir initiation, 6 during favipiravir treatment were included in this study. All patients were administered 1800 mg 7 of favipiravir twice daily as a loading dose on day 1 and 800 mg twice daily as a maintenance 8 dose from day 2 and thereafter. 9

A retrospective chart review was performed for all individuals in the study to identify basic 11 demographic and clinical characteristics, medical history and comorbidities, clinical presentation 12 and severity, possible adverse effects of favipiravir, treatment duration, and concomitant 13 medications. Severity was divided into five categories: asymptomatic; mild (symptomatic 14 patients without pneumonia); moderate (pneumonia patients without required oxygen 15 supplementation); severe (required oxygen supplementation); and critically ill (requiring 16 invasive mechanical ventilation, shock, and/or multiple organ dysfunction). Hematological and 17 serum chemistry analyses performed during hospitalization, even after the end of favipiravir 18 treatment, were retrieved and compared over time. 19

Regarding the definition of liver injury, the laboratory threshold criteria used to identify 21 episodes of drug-induced liver injury and their clinical pattern (hepatocellular, cholestatic, or 22 mixed) were based on international Drug-Induced Liver Injury (DILI) Expert Working Group 23

Standards [8] . For hepatocellular liver injury, we required liver chemistry thresholds of alanine 24 transferase (ALT) ULN and 2 < R < 5 [8] . The earliest liver chemistry elevations meeting the threshold 28 criteria were used to determine the clinical pattern and liver injury date. The ALP values 29 measured using the Japan Society of Clinical Chemistry method (x) were converted to the 1 International Federation of Clinical Chemistry and Laboratory Medicine method (y) using the 2 following formula: y=0.35x. The Roussel Uclaf Causality Assessment Method (RUCAM), which 3 is the most widely used method to assess causality in drug-induced liver injury, was used to 4 assess the causality between favipiravir and liver injury [9]. 5

Steady-state serum C min was defined as the total concentration collected 9-15 h after the 7 dose and before administration of favipiravir at ≥ 48 h after favipiravir initiation. Favipiravir 8 concentrations were determined using residual serum samples from the clinical examination, and 9 the serum samples collected from the patients were stored in a freezer (-80°C) until measurement. 10

The times of oral administration and blood collection were carefully checked, and samples 11 deemed inappropriate were excluded from the analysis. Favipiravir concentrations in the serum 12

were determined using high-performance liquid chromatography (Shimadzu Corp., Kyoto, 13 Japan). Favipiravir (CAS No.: 259793-96-9) was purchased as a bulk powder from Cosmo Bio 14

Co., Ltd. (Tokyo, Japan). Separation was carried out on an aminopropyl column (Unison UK-15

Amino, 150 × 3 mm, 3 μm; Imtakt Co., Kyoto, Japan), and 0.1% acetic acid solution was used as 16 the mobile phase. The lower limit of quantification was 0.5 mg/L (coefficient of variation < 17 10%), and the lower limit of detection was 0.1 mg/L. 18

Continuous and categorical variables are presented as median (interquartile range) and n 20 (%), respectively. We used the Mann-Whitney U test, χ 2 test, or Fisher's exact test to compare 21 the differences between patients with and without favipiravir-induced liver injury. Data were 22 analyzed using JMP Pro version 15.0.0 software (SAS Institute Inc., Cary, NC, USA). 23

This study was performed as per the Declaration of Helsinki and was approved by the 25 Ethical Review Board of the University of Toyama (approval numbers: R2019167 and 26 R2020146) and Nihon University (School of Pharmacy, approval number: 20-005). Written 27 informed consent was obtained from all patients. 28 1

Demographics and clinical characteristics of all nine patients (seven men and two 4 women) treated with favipiravir are summarized in Tables 1 and 2. The median age of the 5 patients was 62 years (range, 53-90 years). Hypertension was the most common comorbidity, 6 followed by dyslipidemia and diabetes. There were no patients with the hepatic disease with 7 impaired liver function; however, two patients demonstrated fatty liver on computed tomography 8 at admission. Three patients habitually ingested alcohol, which was defined as > 2 drinks per day 9 (> 14 units/week) for women and > 3 drinks per day (> 21 units/week) for men, and 10 g ethanol 10 for each drink. Regarding the severity of COVID-19, two patients had moderate disease, five had 11 severe disease, and the remaining two patients were critically ill. All patients were administered 12 1800 mg of favipiravir twice daily as loading on day 1 and 800 mg twice daily as a maintenance 13 dose from day 2 and thereafter. Favipiravir administration was discontinued in three patients due 14

to favipiravir-induced liver injury in patient 3 and suspected favipiravir-induced drug fever in 15 two patients (patients 2 and 8). 16 Baseline laboratory findings before the administration of favipiravir are also described in 17 Table 2 . There were no significant differences between patients with and without liver injury in 18 terms of patient demographics and clinical characteristics. 19 20

Of the nine patients, favipiravir-induced liver injury developed in three patients during 22 treatment. The severity of liver injury in these three episodes (patients 3, 4, and 5) assessed using 23 the DILI severity index was mild with two classified as cholestatic (patients 3 and 4) and one as 24 hepatocellular injury (patient 5), with a score of four (possible), seven (probable), and three 25 (possible) based on the Research Center of Integrative Molecular Systems (CIMOS)/RUCAM 26 scoring system. Other medications are also being considered; however, there has been no 27 obvious relevance based on the clinical course. Among the three patients with favipiravir-28 induced liver injury, the median (range) time from the initiation of therapy to the development of 29 liver injury was 13 (11) (12) (13) (14) days. The liver injury occurred during the remission of COVID-19 in 1 all three patients, and the RT-qPCR results using nasopharyngeal swabs obtained 1-4 days after 2 the development of liver injury, were negative; however, were confirmed after the end of 3 favipiravir administration. One of three patients required discontinuation of favipiravir before the 4 planned treatment duration; however, abnormal liver blood test results gradually improved after 5 the end of favipiravir treatment in all patients. Median (range) favipiravir C min at steady state was 6 found to be significantly higher in patients with liver injury at 66.4 (47.8-72.4) mg/L than in 7 those without injury at 12.8 (9.4-21.8) mg/L (P = 0.028; Figure 1 ). 8 9

A total of 30 observed favipiravir trough concentrations were collected from nine patients. 11

The median (range) C min was 20. 

Elevated liver function tests and/or liver injury are important adverse effects of 18 favipiravir observed frequently in clinical trials [5, 6] . Since abnormal liver function tests (LFTs) 19 are affected by various factors, including concomitantly administered drugs, underlying liver 20 disease, and disease severity, case reports of favipiravir-induced liver injury are still few [7] and 21 no previous study has reported an association between favipiravir-induced liver injury and serum 22

concentrations. 23

The clinical trial US109, a human study of favipiravir that looked specifically at hepatic 24 impairment, reported that mild and moderate hepatic impairment (Child-Pugh Turcotte score A 25 and B) resulted in 2.1-and 2.0-fold increases in favipiravir exposure, respectively [10] . It may 26 appear that high serum concentration was not the cause of favipiravir-induced liver injury, but 27 subsequent results of favipiravir administration in patients with hepatic impairment. However, 28 high favipiravir serum C min was observed before the occurrence of favipiravir-induced liver 1 injury, there were no patients with hepatic impairment and abnormal LFTs at baseline, and 2 elevated liver function tests were recovered after discontinuation or end of favipiravir during 3 hospitalization. 4

Another factor that should be considered is the potential role of liver damage caused by 5 SARS-CoV-2. The incidence of LFT abnormalities in patients with COVID-19 varies among 6 studies [11] [12] [13] ; however, it may be present in up to half of the hospitalized patients with SARS-7

CoV-2 [14, 15] . Previous studies have indicated that the hepatocellular pattern is the most 8 frequent LFT abnormality [11] [12] [13] . These alterations have largely been reported as mild-to-9 moderate elevations in serum transaminases. In contrast, Yeoman et al. reported that 31% of 318 10 hospitalized patients with COVID-19 had one or more abnormal liver function tests and had 11 abnormal admission in 64%, and cholestatic patterns dominated [15] . These gaps still exist, due 12 to the largely unknown pathogenesis of liver damage by SARS-CoV-2, and other potential 13 confounding factors, including systemic organ failure in critically ill patients and the effect of the 14 administered drugs, also preclude detailed analysis of the causes of abnormal LFTs. The present 15 study included five severe and two critically ill patients; however, liver injury in three patients 16 (two severe and one critically ill) occurred not on admission, but after the clinical remission, 17 inconsistent with the liver injury as a consequence of the systemic inflammation developed in 18 response to the SARS-CoV-2. Other concomitant medications were also considered; however, no 19 improvement was observed after discontinuation of the medications, and the relevance was 20 difficult to determine. 21

To the best of our knowledge, there is only one case report of favipiravir-induced liver 22 injury, despite the high frequency of abnormal LFTs and/or liver injury in clinical studies of 23 favipiravir among patients with COVID-19 [7] . Yamazaki et al. [7] reported that a 73-year-old 24 patient with a history of alcoholic hepatitis received favipiravir at 6000 mg/day on the first day 25 and 2400 mg/day from the second day for 14 days; however, subsequently developed a 26 favipiravir-induced cholestatic liver injury with a score of 6 (possible) based on the R factor and 27 CIMOS/RUCAM scoring system [9] . This case report also suggested that favipiravir exposure 28 may have contributed to drug-induced liver injury; however, favipiravir concentrations were not 29 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ;  measured. In the present study, three episodes were classified as two cholestatic and one 1 hepatocellular liver injury, with a score above three (possible). 2

Favipiravir may also possibly cause liver damage from the viewpoint of its chemical 3 structure. Pyrazinamide, an antituberculosis drug, has a typical side effect of hepatotoxicity, with 4 unclear mechanism; however, is dose-dependent [16] . Favipiravir is structurally quite similar to 5 pyrazinamide and may be regarded as a potentially hepatotoxic drug in a dose-dependent manner. 6

The number of patients involved was quite small, which was a limitation of this study. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Numbers represent each patient number, and the red color represents favipiravir concentrations after introducing continuous hemodiafiltration (CHDF).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Geneva: World Health Organization

A case of COVID-19 diagnosed with favipiravir induced drug fever based on positive drug-induced lymphocyte stimulation test

A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?

Uric acid elevation by favipiravir, an antiviral drug

A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19

Case definition and phenotype standardization in drug-induced liver injury

Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

COVID-19: Abnormal liver function tests

Acute liver injury in COVID-19: Prevalence and association with clinical outcomes in a large U

Abnormal liver blood tests among hospitalised patients with SARS-CoV2 (COVID-19)

Incidence, pattern and severity of abnormal liver blood tests among hospitalised patients with SARS-COV2 (COVID-19) in South Wales

Hepatotoxicity of pyrazinamide: cohort and case-control analyses